ARTICLE | Deals
Expanded deal with Kyowa could give MEI cash through drug approval
April 14, 2020 2:36 PM UTC
Updated on Apr 14, 2020 at 9:13 PM UTC
Building on a 2018 deal in Japan, MEI Pharma granted Kyowa Kirin ex-U.S. rights to its PI3Kδ inhibitor ME-401 in an expanded partnership that could shore up the San Diego-based biotech’s balance sheet through a regulatory approval.
MEI Pharma Inc. (NASDAQ:MEIP) will receive $100 million up front in Tuesday’s deal and is eligible for $582.5 million in milestones, plus royalties. The partners will co-promote the therapy in the U.S., splitting costs and profits equally...
BCIQ Company Profiles
BCIQ Target Profiles